In this episode, I take you behind the scenes of ECTRIMS 2025 and explore seven fascinating studies that show how multiple sclerosis (MS) care is evolving — from safety monitoring and infection risks to data-driven, personalized treatment decisions.

You'll learn about:

• How often late-onset neutropenia occurs in people on Rituximab and who's most at risk.

• What factors increase the chance of serious infections with Ocrelizumab.

• Why early high-efficacy treatment leads to better long-term outcomes across four countries.

• What happens to memory B cells during long-term Ocrelizumab therapy and what that means for extended dosing intervals.

• What the FAERS database tells us about tumor signals and why HPV vaccination remains essential for women with MS.

• How real-world data from the TEMPOS study (France) reveal a massive shift toward anti-CD20 therapies — especially Ofatumumab.

• And finally, how a new AI-based prediction tool helps estimate individual risk when stopping a DMT.

🎯 Main takeaway: MS treatment is moving toward earlier, stronger, and more personalized approaches — guided by real-world evidence and smart technology.

👉 You can read the full article with all study details, numbers, and takeaways here: https://ms-perspektive.de/en/140-ectrims-rwe

---

See you soon and try to make the best out of your life, Nele

For more information and positive thoughts, subscribe to my newsletter for free.

Click here for an overview of all podcast episodes published so far.